Core Insights - Inflection Resources Ltd. has successfully completed the acquisition of the Endurance Projects, a significant portfolio of copper-gold projects in Australia's Northern Territory, enhancing its exploration strategy [2][6][37] Project Overview - The Endurance Projects consist of twelve exploration licenses covering a total area of 4,592 km², strategically located near a major geological structure that may localize IOCG copper-gold mineralization [3][6] - The licenses include sixteen principal target areas characterized by geophysical anomalies similar to those found at major IOCG deposits like Ernest Henry and Olympic Dam [4][6] Geological Context - The area is covered by younger rocks and alluvium, with thickness ranging from 60 to 170 m, which has historically hindered exploration efforts [5][6] - Modern exploration techniques, including high-resolution geophysical surveys, are now being employed to test these concealed targets effectively [5][6] Target Areas - The Bigeye target is identified as the highest priority, defined by an 8 km × 8 km aeromagnetic high and associated with a Bouguer gravity anomaly, indicating potential for IOCG-style mineralization [10][14] - The Barreleye target is characterized by a 2.5 km × 0.5 km magnetic high, suggesting a dense magnetic center and potential for sulphide accumulation [16] Exploration Strategy - The company is prioritizing target assessment through data compilation and engagement with Aboriginal stakeholders, applying a mineral systems approach to maximize exploration potential [2][6] - A program of first-pass air-core drilling is planned for the first half of the following year, aimed at testing the identified targets [31] IOCG Deposit Significance - IOCG deposits are among the most metal-rich mineral systems globally, with significant examples in Australia, including Olympic Dam and Ernest Henry, which serve as exploration models for the Endurance Projects [32][33] - The potential for large-scale IOCG deposits in the Endurance Projects is underscored by the favorable geological and geophysical characteristics observed [6][32]

Core Viewpoint - Credissential Inc. is unable to file its annual financial statements by the deadline due to audit delays, resulting in a Management Cease Trade Order being granted [1][2]. Group 1: Audit Delays - The delay in completing the audit is attributed to the complexity of the financial reporting period, which involved consolidating two acquisitions and convertible note financings [2]. - Additional audit procedures were required for purchase price allocations, fair value assessments, and financial instrument accounting, extending beyond the initial timeline [2]. Group 2: Filing Expectations - The Company expects to file the Annual Filings on or before November 29, 2025, and will announce the completion through a news release [3]. - In the meantime, the Company will issue bi-weekly default status reports as per the alternative information guidelines during the MCTO [3]. Group 3: Management Cease Trade Order (MCTO) - During the MCTO, the general investing public can continue to trade the Company's common shares, but the CFO and CEO are prohibited from trading until the Annual Filings are submitted [4]. - The Company confirms it is not subject to any insolvency proceedings and has disclosed all material information regarding its affairs [5][9].

Core Viewpoint - Plaid Technologies Inc. has successfully closed the second tranche of its non-brokered private placement, raising a total of $976,000 from both tranches combined, which will be used to support various operational and developmental activities [1][2][3]. Fundraising Details - The second tranche consisted of 100,000 common shares issued at $1.25 per share, generating $125,000 in proceeds [1]. - Together with the first tranche closed on October 24, 2025, the total gross proceeds from the Offering amount to $976,000 [2]. Use of Funds - The net proceeds from the Offering will supplement previously disclosed allocations in the Company's Listing Statement dated August 13, 2025. The breakdown of fund usage is as follows: - Sales & Marketing: Originally $45,000, now $50,000 additional - Management and Consulting Fees: Originally $80,000, now $30,000 additional - General & Administrative Expenses: Originally $50,000, now $25,000 additional - Development Fees: Originally $170,000, now $50,000 additional - Unallocated Working Capital: Originally $10,000, now $821,000 additional - Total: Originally $355,000, now $976,000 total raised [3][10]. Company Overview - Plaid Technologies focuses on developing and commercializing graphene-enhanced technology, particularly a proprietary graphene-infused concrete mixture aimed at applications in wellbore cement and subsurface projects [4]. - The management anticipates that this unique mixture will revolutionize well abandonment processes by integrating advanced materials with precise engineering [4].

Core Viewpoint - Voyageur Pharmaceuticals Ltd. has signed a Non-Exclusive Distribution Agreement with Phalanx to expand its market presence in Mexico's healthcare sector, particularly in barium-based contrast media products [1][2][4]. Company Overview - Voyageur Pharmaceuticals is a Canadian public company focused on developing cost-effective imaging contrast media products, specifically barium and iodine Active Pharmaceutical Ingredients (API) [8]. - The company aims to become a key player in the contrast media market by vertically integrating its production processes, ensuring quality and cost efficiency [11]. Partnership Details - The agreement with Phalanx represents a strategic partnership aimed at driving market expansion into Mexico, with Phalanx responsible for registering and distributing Voyageur's products [2][4]. - Phalanx is a leading pharmaceutical distributor in Mexico with over 20 years of experience in the health sector, providing market entry strategies and ensuring regulatory compliance [3][5]. Market Strategy - This partnership is a significant milestone in Voyageur's international growth strategy, targeting underserved markets with increasing demand for high-quality contrast media [4]. - The sales of Voyageur's products in Mexico will depend on local regulatory approval processes, with Phalanx leading the necessary filings [4]. Operational Focus - Voyageur's Frances Creek Project is central to its business plan, aiming to produce high-quality barium sulfate contrast media that can replace less effective synthetic products currently dominating the market [10]. - The company is committed to responsible sourcing and manufacturing practices, encapsulated in its motto "From the Earth to the Bottle" [11].

Core Viewpoint - Blackbird Critical Metals Corp. has received conditional approval from the Canadian Securities Exchange for its acquisition of Lir Life Science Inc. and the listing of the resulting issuer's common shares upon completion of the acquisition [1][11]. Acquisition Details - The company will acquire 100% of Lir Life Sciences' common shares in exchange for issuing 22,312,678 common shares of Blackbird on a post-consolidation basis to Lir shareholders [3]. - Following the acquisition, the business will continue under the name "Lir Life Sciences Corp." [3]. Share Consolidation - Prior to the acquisition closing, Blackbird will consolidate its shares on a 1.5:1 basis, reducing the number of outstanding shares from approximately 7,762,912 to about 5,175,275 [4][5]. - Registered shareholders will receive instructions for exchanging their existing certificates for post-consolidation shares [6]. Financial Transactions - The acquisition includes a transaction fee of 2% of the acquisition value, payable in 379,000 Resulting Issuer Shares [8]. - Lir Life Sciences has completed a private placement of 3,050,270 subscription receipts at $0.35 each, raising approximately $1.07 million, which will convert into Lir Shares prior to closing [9]. - Lir Life Sciences has settled $109,343 in debt by issuing 312,408 Lir Shares at a deemed price of $0.35, which will also convert into Resulting Issuer Shares upon closing [10]. Trading and Regulatory Approval - Trading in Blackbird Shares will remain halted until all conditions for listing are satisfied, including the completion of the acquisition and final approval from the CSE [11]. - The new CUSIP and ISIN numbers for the post-consolidation shares will be 50206C100 and CA50206C1005, respectively [7].

Core Insights - Argenta Silver Corp. has successfully completed its first year of operations, establishing a strong team and gaining recognition in the market [6][20] - The company aims to become a leading silver producer in Latin America, focusing on exploration and production across multiple operations [8] - Significant financial backing has been secured, with C$35 million raised, of which only C$12 million has been spent on operations and acquisitions [10] Company History and Development - The acquisition of the El Quevar Project was finalized on October 24, 2024, marking a pivotal moment for Argenta Silver [2][20] - The company has built a culturally diverse team and established a reputation for transparency and results, attracting major institutional investors [6][9] - The CEO, Joaquin Marias, has a background in geology and has been involved in the El Quevar project since 2010 [3][4] Financial Performance and Capital Allocation - Argenta Silver raised C$15.3 million through a private placement to capitalize the company, with significant investments from notable shareholders [2][10] - The company plans to allocate approximately 40% of its upcoming capital expenditure towards resource expansion and 60% towards exploration [14] Exploration and Technical Achievements - The company has conducted extensive geological work, including re-logging 29,000 meters of historical drill core and detailed mapping of 133 km² [10] - Recent drilling results have shown high silver grades, with surface results exceeding 20,000 g/t Ag and notable drill intercepts of 1.05 meters at 18,467 g/t Ag [18] - The foundational mineral resource estimate of the Yaxtché deposit includes an indicated resource of 45.3 million ounces of silver at a grade of 482 g/t Ag [21] Future Plans and Vision - Argenta Silver is set to embark on a larger drilling campaign, planning 12,000 to 15,000 meters of drilling and geophysical surveys in previously unexplored areas [13][14] - The company aims to unlock the potential of the El Quevar project, which has been dormant for ten years under previous management [16] - The strategic approach focuses on balancing resource area drilling with exploration to maximize value and uncover new deposits [17]

Core Viewpoint - Helix BioPharma Corp. reported a net loss of $5,205,000 for the fiscal year ended July 31, 2025, showing an improvement from a loss of $9,264,000 in the previous year, indicating progress in financial management and operational focus [2][13]. Financial Performance - The total comprehensive loss for the year was $5,205,000, translating to a loss of $0.09 per common share, compared to a loss of $0.21 per common share in the previous year [2][13]. - Research and Development expenses decreased by 40% to $3,558,000 from $5,977,000 in the previous year, attributed to the conclusion of a Phase Ib/II study and changes in stock-based compensation [8][9]. - Operating, general, and administration expenses also saw a significant reduction of 43%, totaling $1,839,000 compared to $3,262,000 in the prior year, primarily due to changes in service providers [10][11]. Clinical Development - The Phase Ib/II trial (LDOS006) for metastatic pancreatic adenocarcinoma was completed in October 2024, with ongoing data analysis and a Clinical Study Report expected in fall 2025 [3]. - A new Phase Ib/Randomized Phase II study (LDOS007) is in planning to assess L-DOS47 in combination with pembrolizumab for NSCLC, with positive feedback received from the FDA regarding the study design [4][6]. Corporate Development - The company decided to focus on developing L-DOS47 as a combination therapy for NSCLC, terminating collaborations with external research institutions that did not align with this focus [6]. - The company closed its laboratory in Edmonton, Canada, on October 31, 2024, and liquidated laboratory equipment while securing important documents and samples [6]. Capital and Liquidity - As of July 31, 2025, the company reported a working capital deficiency of $2,807,000 and an accumulated deficit of $215,876,000, indicating challenges in liquidity [13][18]. - The company closed a non-brokered private placement of 2,222,333 common shares at $0.75 per share, raising gross proceeds of $1,667,000 [7]. Research & Development Focus - The company’s pipeline includes L-DOS47, which targets CEACAM6-expressing tumors, and two pre-IND candidates: LEUMUNA™ and GEMCEDA™, aimed at addressing significant unmet medical needs in oncology [20].

Core Points - Baru Gold Corp. has appointed Keith Margetson to its board of directors, bringing over 40 years of public accounting experience [1][2] - Margetson has served as CFO for several publicly traded companies and is a qualified Canadian CPA and US Certified Public Accountant [2] - The company granted 300,000 stock options to Margetson, allowing him to purchase shares at an exercise price of $0.07 for two years, pending TSX Venture Exchange approval [2] Company Overview - Baru Gold Corporation is a junior gold developer with NI 43-101 gold resources located in Indonesia, a leading gold-producing country [3] - The company is based in both Indonesia and North America, with a team experienced in operating small-scale gold and coal assets [3] - Baru is positioned to become Indonesia's next gold producer, indicating growth potential in the mining sector [3]

Core Points - Hi-View Resources Inc. will present and host an exhibitor booth at the 51st Annual New Orleans Investment Conference from November 2–5, 2025 [1] - The corporate presentation titled "Unlocking District-Scale Gold, Silver, and Copper Opportunities in BC's Prolific Toodoggone District" is scheduled for November 5th at 9:40 a.m. [2] - CEO R. Nick Horsley expressed excitement about participating in the conference and highlighted Hi-View as a below-the-radar investment opportunity compared to peers [3] Company Overview - Hi-View Resources Inc. is a publicly listed mineral exploration company on the Canadian Securities Exchange, focusing on gold, silver, and copper assets in the Toodoggone region of northern British Columbia [6] - The company holds 100% ownership or options on projects covering over 27,791 hectares, including the flagship Golden Stranger Project, Lawyers claims, and Borealis Project, all designated as high-priority targets [6] - Additional properties under option include Saunders, Northern Claims, Nub, and Harmon Peak, with an extra 1,300 hectares currently under mineral claim application [6]

Core Insights - Ventripoint Diagnostics Ltd. has partnered with Providence Health Care Ventures to validate its VMS+™ platform at St. Paul's Hospital, aiming to reduce reliance on cardiac MRI through AI-enhanced echocardiography [1][4] - The VMS+™ platform generates 3-D heart models from 2-D echocardiography images and has shown clinical agreement with MRI measurements, potentially allowing some patients to avoid MRI altogether [2][3] - The collaboration seeks to assess the performance of VMS+™ in real-world settings, focusing on workflow integration, MRI referral reductions, and cost efficiencies [4][5] Company Overview - Ventripoint is recognized for its application of AI in echocardiography, with its VMS products utilizing proprietary Knowledge Based Reconstruction technology to provide accurate cardiac measurements comparable to MRI [7][8] - The VMS+™ platform is FDA-cleared and Health Canada-licensed, compatible with existing 2D ultrasound systems, which allows healthcare systems to enhance imaging capacity without the need for new equipment [2][8] Clinical Evidence - VMS+™ has been successfully implemented in various clinical settings, including the Hospital for Sick Children and Mayo Clinic, demonstrating its effectiveness in aligning echo-derived measurements with cardiac MRI [3] - Recent presentations at conferences have highlighted the platform's ability to provide results comparable to MRI, particularly in assessing adult congenital heart defect patients [3] Future Prospects - The collaboration with PHC Ventures is set to begin in November 2025, with implementation expected in early 2026, aiming to validate the impact of VMS+™ across different healthcare settings [6] - The technology is anticipated to improve access to advanced cardiac diagnostics, especially in rural and Indigenous communities where MRI availability is limited [5][6]